FGFR Expression Thresholds for Inhibitor Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting subjects for treatment with FGFR inhibitors lack clear criteria, as existing practices often treat tumors with any genetic alterations in FGFR genes without determining specific responsiveness, leading to suboptimal treatment outcomes.
Innovation Solution
A method is developed to identify subjects likely to respond to Compound A, an FGFR inhibitor, by determining the expression levels of FGFR1, FGFR2, and FGFR3 in tumors or liquid biopsies, using pre-established threshold levels based on mRNA expression, which correlates with treatment efficacy, specifically considering overexpression levels above 44% to 73% to ensure effective treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If subjects are treated with FGFR inhibitors without clear selection criteria, then more subjects can be treated, but treatment efficacy decreases due to suboptimal responses
Solution Approach 1:
The patent applies parameter changes by establishing specific quantitative thresholds for FGFR expression levels (e.g., FGFR1 > 0.104, FGFR2 > 0.257, FGFR3 > 0.128 normalized to median of reference genes) to identify responsive subjects. This transforms the selection process from subjective judgment to objective parameter-based classification, improving treatment efficacy while maintaining operational simplicity.
2Measurement precision
If FGFR expression levels are determined using mRNA expression thresholds, then treatment response prediction accuracy improves, but measurement and analysis complexity increases
Solution Approach 1:
The patent replaces complex functional assays and in vivo testing with mRNA expression measurement using standardized molecular biology techniques (qRT-PCR, RNA-seq). This substitution achieves high prediction accuracy through direct molecular quantification while avoiding the complexity of phenotypic assays and clinical trial enrollment requirements.
Solution Approach 2:
The patent employs universal mRNA measurement techniques (qRT-PCR, RNA-seq) that can detect multiple FGFR isoforms and related genes simultaneously. This multi-functional approach allows comprehensive assessment of FGFR pathway activation through a single analytical platform, improving precision without proportionally increasing measurement difficulty.
3Measurement precision
If expression threshold levels are established based on extensive analysis, then subject identification accuracy improves, but time and resource investment increases
Solution Approach 1:
The patent performs preliminary action by establishing FGFR expression thresholds using extensive analysis of cell line and patient tumor data before clinical implementation. These pre-determined thresholds (e.g., 73rd percentile cutoffs) are validated and stored for rapid application, eliminating the need for time-consuming analysis during patient selection and enabling immediate deployment in clinical settings.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A method of selecting a subject suffering from a cancer for a therapeutic regimen of administration of a pharmaceutical composition comprising an effective amount of an FGFR inhibitor is described, which method comprises (1) the taking of a tumor or liquid biopsy from the subject; (2) determination of the level of expression of any or all of FGFR1, FGFR2 and FGFR3, and (3) comparison of the determined level of expression of at least one of FGFR1, FGFR2 and FGFR3 with a pre-established threshold value, and declaring the subject eligible for the therapeutic regimen if the determined level exceeds the threshold value. The invention also relates to a method of personalized cancer therapy comprising selection of a subject by the above-described method and subjecting the subject to a therapeutic regimen that comprises administration of a pharmaceutical composition comprising an effective amount of an FGFR inhibitor.